3 May 2016 - AstraZeneca Canada announced today that Health Canada has approved Lynparza (olaparib) capsules as a maintenance treatment for patients with platinum-sensitive relapsed BRCA mutated (germline or somatic) high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer.

Lynparza is the first poly ADP-ribose polymerase (PARP) inhibitor available in Canada, and has been granted the Health Canada Notice of Compliance with Conditions, based on promising evidence of clinical efficacy and duration of response data.

For more details, go to: http://www.wdrb.com/story/31872910/health-canada-approves-lynparza-for-the-treatment-of-ovarian-cancer-in-patients-with-brca-mutations